| Gene symbol |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
| Adcy5 |  |
NM_001012765 |
adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] |
KLA | 1.06 |
1.00 |
.97 |
1.01 |
1.03 |
.95 |
.93 |
| ATP | .95 |
1.08 |
1.08 |
1.07 |
.97 |
1.03 |
.97 |
| KLA/ATP | .97 |
.92 |
1.04 |
.99 |
.91 |
.96 |
1.04 |
|
AK085608
|  |
AK085608 |
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630046G10 product:unclassifiable, full insert sequence. [AK085608] |
KLA | .89 |
.96 |
1.01 |
1.03 |
.96 |
.98 |
1.07 |
| ATP | 1.03 |
1.00 |
.96 |
1.01 |
1.05 |
1.04 |
1.00 |
| KLA/ATP | 1.00 |
1.00 |
.99 |
1.04 |
1.01 |
.99 |
1.00 |
|
| Alox12 |  |
NM_007440 |
arachidonate 12-lipoxygenase (Alox12), mRNA [NM_007440] |
KLA | 1.35 |
1.36 |
1.42 |
1.25 |
1.25 |
1.13 |
1.15 |
| ATP | 1.05 |
1.01 |
1.03 |
1.04 |
1.04 |
1.42 |
1.20 |
| KLA/ATP | 1.36 |
1.29 |
1.23 |
1.26 |
1.24 |
1.31 |
1.80 |
|
| Alox12b |  |
NM_009659 |
arachidonate 12-lipoxygenase, 12R type (Alox12b), mRNA [NM_009659] |
KLA | 1.09 |
1.09 |
1.18 |
1.15 |
1.14 |
1.28 |
1.26 |
| ATP | .99 |
.92 |
1.09 |
1.07 |
1.03 |
1.10 |
1.29 |
| KLA/ATP | 1.16 |
1.20 |
1.27 |
1.30 |
1.21 |
1.19 |
1.30 |
|
| Alox12e |  |
NM_145684 |
arachidonate lipoxygenase, epidermal (Alox12e), mRNA [NM_145684] |
KLA | .97 |
.99 |
1.05 |
.94 |
.99 |
1.01 |
.96 |
| ATP | 1.00 |
.97 |
1.01 |
.98 |
1.01 |
1.01 |
.94 |
| KLA/ATP | .99 |
.92 |
.91 |
.98 |
.95 |
.95 |
.95 |
|
| Alox15 |  |
NM_009660 |
arachidonate 15-lipoxygenase (Alox15), mRNA [NM_009660] |
KLA | 1.02 |
.93 |
.98 |
.96 |
.98 |
.95 |
.87 |
| ATP | .92 |
.95 |
1.09 |
1.01 |
.98 |
1.00 |
.97 |
| KLA/ATP | .97 |
.95 |
.98 |
.94 |
.98 |
.97 |
.92 |
|
| Alox5 |  |
NM_009662 |
arachidonate 5-lipoxygenase (Alox5), mRNA [NM_009662] |
KLA | .83 |
.87 |
.88 |
.87 |
.71 |
.58 |
.21 |
| ATP | 1.03 |
1.03 |
1.14 |
1.21 |
.93 |
.55 |
.41 |
| KLA/ATP | .86 |
.85 |
.90 |
.97 |
.84 |
.61 |
.24 |
|
| Alox8 |  |
NM_009661 |
arachidonate 8-lipoxygenase (Alox8), mRNA [NM_009661] |
KLA | 1.02 |
.99 |
1.01 |
1.00 |
.99 |
1.06 |
.95 |
| ATP | 1.04 |
.99 |
.86 |
.96 |
.92 |
1.02 |
.95 |
| KLA/ATP | .98 |
.99 |
1.03 |
1.00 |
.98 |
.91 |
.90 |
|
| App |  |
AK030583 |
adult male pituitary gland cDNA, RIKEN full-length enriched library, clone:5330435A13 product:unclassifiable, full insert sequence [AK030583] |
KLA | 1.63 |
1.38 |
1.53 |
1.57 |
1.73 |
1.36 |
1.08 |
| ATP | 1.12 |
1.12 |
.89 |
1.54 |
2.87 |
1.39 |
.99 |
| KLA/ATP | 1.48 |
1.08 |
1.13 |
1.26 |
2.11 |
1.64 |
1.18 |
|
| App | |
NM_007471 |
amyloid beta (A4) precursor protein (App), mRNA [NM_007471] |
KLA | 1.42 |
1.48 |
1.56 |
1.38 |
1.57 |
1.42 |
1.38 |
| ATP | 1.08 |
1.09 |
.33 |
.50 |
.67 |
1.24 |
1.14 |
| KLA/ATP | 1.57 |
1.59 |
.60 |
.78 |
.45 |
.87 |
1.22 |
|
| Araf |  |
NM_009703 |
v-raf murine sarcoma 3611 viral oncogene homolog (Araf), mRNA [NM_009703] |
KLA | .87 |
.80 |
.89 |
.93 |
1.10 |
1.19 |
1.16 |
| ATP | 1.09 |
1.11 |
1.19 |
1.18 |
.78 |
.53 |
1.18 |
| KLA/ATP | 1.00 |
.95 |
.99 |
.93 |
.63 |
.55 |
1.27 |
|
BB548379
|  |
BB548379 |
gb|BB548379 RIKEN full-length enriched, 2 days pregnant adult female oviduct Mus musculus cDNA clone E230007L20 3. [BB548379] |
KLA | .98 |
1.05 |
1.00 |
.99 |
1.04 |
1.04 |
1.05 |
| ATP | 1.01 |
.98 |
1.01 |
1.02 |
.98 |
1.08 |
.92 |
| KLA/ATP | .98 |
1.06 |
1.03 |
1.03 |
1.00 |
1.00 |
.99 |
|
BI102035
|  |
BI102035 |
gb|602887753F1 NCI_CGAP_Kid14 Mus musculus cDNA clone IMAGE:5043156 5, mRNA sequence [BI102035] |
KLA | 1.00 |
.99 |
1.05 |
.97 |
1.03 |
1.04 |
1.06 |
| ATP | .99 |
.97 |
1.02 |
1.06 |
1.02 |
.98 |
1.02 |
| KLA/ATP | 1.05 |
.98 |
1.13 |
1.03 |
1.00 |
1.08 |
1.33 |
|
| Braf |  |
NM_139294 |
Braf transforming gene (Braf), mRNA [NM_139294] |
KLA | 1.52 |
1.57 |
1.55 |
1.33 |
1.83 |
1.52 |
1.60 |
| ATP | 1.08 |
1.17 |
1.02 |
1.37 |
.95 |
1.15 |
.95 |
| KLA/ATP | 1.64 |
1.69 |
1.39 |
1.51 |
1.04 |
1.31 |
1.26 |
|
| Cacna1a |  |
NM_007578 |
calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (Cacna1a), mRNA [NM_007578] |
KLA | .71 |
.66 |
.61 |
.63 |
.60 |
.71 |
.72 |
| ATP | 1.07 |
1.04 |
.89 |
1.08 |
.71 |
.56 |
.75 |
| KLA/ATP | .71 |
.72 |
.85 |
.69 |
.64 |
.63 |
.68 |
|
| Cacna1b |  |
U04999 |
N-type calcium channel alpha1 subunit mRNA, complete cds [U04999] |
KLA | .94 |
.94 |
.95 |
.88 |
1.09 |
.85 |
.92 |
| ATP | 1.06 |
1.17 |
1.00 |
1.24 |
1.59 |
1.15 |
1.17 |
| KLA/ATP | .91 |
.91 |
.95 |
.95 |
.90 |
.97 |
1.01 |
|
| Cacna1d |  |
NM_001083616 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 2, mRNA [NM_001083616] |
KLA | 1.57 |
1.58 |
2.50 |
3.62 |
4.55 |
2.93 |
.99 |
| ATP | 1.12 |
.99 |
.97 |
.94 |
.75 |
1.71 |
1.48 |
| KLA/ATP | 1.47 |
1.51 |
1.82 |
1.56 |
1.67 |
2.93 |
4.60 |
|
| Cacna1d | |
NM_028981 |
calcium channel, voltage-dependent, L type, alpha 1D subunit (Cacna1d), transcript variant 1, mRNA [NM_028981] |
KLA | 1.20 |
1.26 |
1.43 |
1.62 |
2.07 |
1.66 |
1.00 |
| ATP | 1.03 |
1.03 |
.97 |
.97 |
.93 |
1.20 |
1.26 |
| KLA/ATP | 1.16 |
1.12 |
1.10 |
1.14 |
1.08 |
1.44 |
2.56 |
|
| Cacna1f |  |
NM_019582 |
calcium channel, voltage-dependent, alpha 1F subunit (Cacna1f), mRNA [NM_019582] |
KLA | 1.03 |
.98 |
1.05 |
1.06 |
1.00 |
1.02 |
1.01 |
| ATP | 1.05 |
1.05 |
.95 |
.98 |
.97 |
.96 |
1.01 |
| KLA/ATP | 1.01 |
1.03 |
.94 |
1.01 |
1.01 |
1.00 |
.99 |
|
| Cacna1s |  |
NM_001081023 |
calcium channel, voltage-dependent, L type, alpha 1S subunit (Cacna1s), mRNA [NM_001081023] |
KLA | 1.03 |
1.01 |
.96 |
1.06 |
1.00 |
1.00 |
1.05 |
| ATP | 1.01 |
.98 |
1.02 |
1.02 |
1.05 |
1.07 |
1.05 |
| KLA/ATP | .99 |
1.05 |
1.02 |
1.05 |
1.03 |
1.05 |
1.00 |
|
| Casp3 |  |
NM_009810 |
caspase 3 (Casp3), mRNA [NM_009810] |
KLA | 1.66 |
1.94 |
2.47 |
2.61 |
3.01 |
2.96 |
1.44 |
| ATP | .90 |
.99 |
1.17 |
1.30 |
1.01 |
1.17 |
.86 |
| KLA/ATP | 1.55 |
1.87 |
2.40 |
2.35 |
2.27 |
2.84 |
2.52 |
|
| Casp3 | |
U49929 |
ICE-like cysteine protease (Lice) mRNA, complete cds. [U49929] |
KLA | 1.71 |
1.87 |
2.69 |
3.11 |
3.64 |
3.42 |
1.52 |
| ATP | 1.04 |
1.07 |
1.16 |
1.34 |
.98 |
1.27 |
.86 |
| KLA/ATP | 1.80 |
1.96 |
2.46 |
2.91 |
2.50 |
3.24 |
3.10 |
|
| Cyp2c29 |  |
NM_007815 |
cytochrome P450, family 2, subfamily c, polypeptide 29 (Cyp2c29), mRNA [NM_007815] |
KLA | 1.01 |
.95 |
1.06 |
1.12 |
1.01 |
1.02 |
1.12 |
| ATP | 1.03 |
1.02 |
1.01 |
1.06 |
.98 |
.98 |
.96 |
| KLA/ATP | 1.09 |
1.14 |
1.02 |
.98 |
.99 |
.98 |
.98 |
|
| Cyp2c37 |  |
NM_010001 |
cytochrome P450, family 2. subfamily c, polypeptide 37 (Cyp2c37), mRNA [NM_010001] |
KLA | 1.27 |
1.43 |
1.64 |
1.52 |
1.65 |
1.43 |
1.45 |
| ATP | .99 |
.96 |
1.03 |
1.13 |
1.10 |
1.03 |
1.27 |
| KLA/ATP | 1.37 |
1.49 |
1.22 |
1.46 |
1.16 |
1.12 |
1.24 |
|
| Cyp2c38 |  |
NM_010002 |
cytochrome P450, family 2, subfamily c, polypeptide 38 (Cyp2c38), mRNA [NM_010002] |
KLA | 1.01 |
1.06 |
.98 |
.96 |
1.07 |
.98 |
.97 |
| ATP | 1.01 |
1.09 |
1.04 |
.98 |
1.00 |
1.03 |
.98 |
| KLA/ATP | 1.03 |
.98 |
1.03 |
1.04 |
1.00 |
1.00 |
1.01 |
|
| Cyp2c39 |  |
NM_010003 |
cytochrome P450, family 2, subfamily c, polypeptide 39 (Cyp2c39), mRNA [NM_010003] |
KLA | 1.04 |
1.01 |
.97 |
1.00 |
.99 |
1.01 |
.98 |
| ATP | 1.04 |
1.07 |
.95 |
1.00 |
.96 |
1.03 |
1.01 |
| KLA/ATP | 1.03 |
1.01 |
1.02 |
1.01 |
1.05 |
1.05 |
.99 |
|
| Cyp2c40 |  |
NM_010004 |
cytochrome P450, family 2, subfamily c, polypeptide 40 (Cyp2c40), mRNA [NM_010004] |
KLA | .96 |
1.06 |
1.05 |
1.03 |
.99 |
1.01 |
1.02 |
| ATP | .96 |
1.01 |
1.02 |
.97 |
1.01 |
1.02 |
.99 |
| KLA/ATP | 1.06 |
1.03 |
1.04 |
.98 |
1.05 |
1.01 |
.97 |
|
| Cyp2c44 |  |
NM_001001446 |
cytochrome P450, family 2, subfamily c, polypeptide 44 (Cyp2c44), mRNA [NM_001001446] |
KLA | .98 |
1.04 |
.93 |
1.05 |
1.01 |
.93 |
.94 |
| ATP | 1.02 |
1.01 |
1.01 |
1.04 |
1.02 |
1.02 |
1.00 |
| KLA/ATP | .93 |
.95 |
1.00 |
1.05 |
1.07 |
1.01 |
1.01 |
|
| Cyp2c54 |  |
NM_206537 |
cytochrome P450, family 2, subfamily c, polypeptide 54 (Cyp2c54), mRNA [NM_206537] |
KLA | .98 |
.99 |
1.04 |
.97 |
1.06 |
1.03 |
1.04 |
| ATP | .99 |
.98 |
1.10 |
1.03 |
1.03 |
.98 |
1.03 |
| KLA/ATP | 1.02 |
1.04 |
.89 |
.98 |
.99 |
.93 |
.99 |
|
| Cyp2c55 |  |
NM_028089 |
cytochrome P450, family 2, subfamily c, polypeptide 55 (Cyp2c55), mRNA [NM_028089] |
KLA | .97 |
1.02 |
1.01 |
.99 |
.99 |
1.00 |
.94 |
| ATP | 1.04 |
.98 |
1.09 |
.97 |
1.05 |
.99 |
1.06 |
| KLA/ATP | 1.04 |
1.01 |
1.15 |
1.03 |
1.05 |
1.05 |
1.09 |
|
| Cyp2c65 |  |
AK008688 |
adult male stomach cDNA, RIKEN full-length enriched library, clone:2210009K14 product:similar to CYTOCHROME P450 2C18 (EC 1.14.14.1) (CYPIIC18) (P450-6B [AK008688] |
KLA | .95 |
.97 |
1.02 |
1.00 |
.97 |
1.10 |
1.04 |
| ATP | .98 |
1.05 |
1.00 |
1.10 |
.98 |
.99 |
1.03 |
| KLA/ATP | .96 |
.97 |
.99 |
1.01 |
1.03 |
1.04 |
1.03 |
|
| Cyp2c66 |  |
NM_001011707 |
cytochrome P450, family 2, subfamily c, polypeptide 66 (Cyp2c66), mRNA [NM_001011707] |
KLA | 1.03 |
1.04 |
.99 |
1.00 |
1.06 |
1.11 |
1.01 |
| ATP | .97 |
1.01 |
1.03 |
1.00 |
.98 |
1.03 |
1.04 |
| KLA/ATP | 1.08 |
.97 |
1.15 |
1.02 |
1.04 |
1.06 |
1.08 |
|
| Cyp2c70 |  |
NM_145499 |
cytochrome P450, family 2, subfamily c, polypeptide 70 (Cyp2c70), mRNA [NM_145499] |
KLA | 1.05 |
.94 |
.95 |
.86 |
1.06 |
.96 |
.99 |
| ATP | 1.01 |
.98 |
.69 |
.69 |
.97 |
.87 |
1.09 |
| KLA/ATP | 1.00 |
.97 |
.74 |
.74 |
.81 |
.86 |
1.17 |
|
| Cyp2d10 |  |
NM_010005 |
cytochrome P450, family 2, subfamily d, polypeptide 10 (Cyp2d10), mRNA [NM_010005] |
KLA | .98 |
.99 |
1.04 |
1.07 |
1.04 |
1.08 |
1.10 |
| ATP | 1.02 |
.97 |
1.02 |
1.01 |
.97 |
.95 |
1.06 |
| KLA/ATP | 1.01 |
1.06 |
1.01 |
1.04 |
1.07 |
1.09 |
.99 |
|
| Cyp2d22 |  |
AK086555 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930036L18 product:cytochrome P450, family 2, subfamily d, polypeptide 22, full insert sequence. [AK086555] |
KLA | 1.02 |
.92 |
.95 |
1.00 |
1.00 |
.91 |
.96 |
| ATP | .98 |
.98 |
.97 |
1.10 |
.94 |
1.02 |
.91 |
| KLA/ATP | .97 |
1.00 |
.89 |
1.02 |
.99 |
.99 |
.99 |
|
| Cyp2d22 | |
NM_019823 |
cytochrome P450, family 2, subfamily d, polypeptide 22 (Cyp2d22), mRNA [NM_019823] |
KLA | 1.05 |
.98 |
.94 |
.98 |
1.00 |
.95 |
1.08 |
| ATP | 1.05 |
1.00 |
1.01 |
1.05 |
1.01 |
1.05 |
1.01 |
| KLA/ATP | 1.00 |
1.00 |
.99 |
1.02 |
1.05 |
1.00 |
1.09 |
|
| Cyp2d26 |  |
NM_029562 |
cytochrome P450, family 2, subfamily d, polypeptide 26 (Cyp2d26), mRNA [NM_029562] |
KLA | .94 |
.93 |
.96 |
1.04 |
1.01 |
1.05 |
1.09 |
| ATP | 1.13 |
.93 |
1.08 |
1.10 |
1.14 |
1.12 |
1.05 |
| KLA/ATP | 1.01 |
.96 |
1.00 |
1.10 |
1.26 |
1.14 |
1.17 |
|
| Cyp2d9 |  |
NM_010006 |
cytochrome P450, family 2, subfamily d, polypeptide 9 (Cyp2d9), mRNA [NM_010006] |
KLA | 1.09 |
1.03 |
1.04 |
1.11 |
1.11 |
1.13 |
1.01 |
| ATP | 1.01 |
1.04 |
1.07 |
1.15 |
1.11 |
1.06 |
.96 |
| KLA/ATP | 1.09 |
1.13 |
1.12 |
1.19 |
1.09 |
1.05 |
1.02 |
|
| Cyp2j11 |  |
NM_001004141 |
cytochrome P450, family 2, subfamily j, polypeptide 11 (Cyp2j11), mRNA [NM_001004141] |
KLA | .95 |
1.02 |
1.07 |
.95 |
.95 |
.92 |
.83 |
| ATP | .95 |
1.02 |
1.05 |
.93 |
.92 |
.90 |
1.00 |
| KLA/ATP | 1.05 |
.96 |
1.00 |
.97 |
.90 |
.82 |
.86 |
|
| Cyp2j13 |  |
NM_145548 |
cytochrome P450, family 2, subfamily j, polypeptide 13 (Cyp2j13), mRNA [NM_145548] |
KLA | 1.01 |
.99 |
.98 |
1.00 |
.98 |
.96 |
.92 |
| ATP | .99 |
1.03 |
1.01 |
.98 |
.95 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.03 |
1.02 |
1.03 |
.96 |
.95 |
.96 |
|
| Cyp2j5 |  |
NM_010007 |
cytochrome P450, family 2, subfamily j, polypeptide 5 (Cyp2j5), mRNA [NM_010007] |
KLA | 1.00 |
.99 |
1.05 |
1.01 |
1.00 |
1.06 |
1.06 |
| ATP | .99 |
1.00 |
1.03 |
1.09 |
1.00 |
1.03 |
1.01 |
| KLA/ATP | 1.03 |
.98 |
1.09 |
1.11 |
1.06 |
1.09 |
1.01 |
|
| Cyp2j9 |  |
NM_028979 |
cytochrome P450, family 2, subfamily j, polypeptide 9 (Cyp2j9), mRNA [NM_028979] |
KLA | .84 |
.88 |
.97 |
.91 |
.75 |
.66 |
.66 |
| ATP | 1.10 |
.98 |
.99 |
.92 |
.90 |
.73 |
.64 |
| KLA/ATP | .88 |
.95 |
.93 |
.86 |
.80 |
.78 |
.59 |
|
| Cyp4x1 |  |
AK038526 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230025G20 product:similar to CYTOCHROME P450, 4A family [Mus musculus], full insert sequence [AK038526] |
KLA | 1.00 |
.98 |
1.03 |
1.00 |
1.05 |
1.03 |
1.09 |
| ATP | 1.01 |
.99 |
.98 |
1.02 |
1.04 |
1.04 |
1.13 |
| KLA/ATP | 1.02 |
1.07 |
1.08 |
1.01 |
1.00 |
1.06 |
1.10 |
|
| Ddc |  |
NM_016672 |
dopa decarboxylase (Ddc), mRNA [NM_016672] |
KLA | 1.27 |
1.28 |
1.34 |
1.33 |
1.34 |
1.21 |
1.05 |
| ATP | 1.02 |
.99 |
1.05 |
.98 |
1.02 |
1.02 |
1.14 |
| KLA/ATP | 1.24 |
1.22 |
1.28 |
1.25 |
1.12 |
1.20 |
1.35 |
|
| Dusp1 |  |
NM_013642 |
dual specificity phosphatase 1 (Dusp1), mRNA [NM_013642] |
KLA | 4.56 |
3.88 |
6.42 |
8.88 |
7.87 |
4.61 |
3.97 |
| ATP | 4.35 |
6.31 |
15.22 |
22.62 |
6.79 |
7.21 |
2.84 |
| KLA/ATP | 5.44 |
7.70 |
16.61 |
23.52 |
9.62 |
11.17 |
12.72 |
|
| Gabrb1 |  |
NM_008069 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 1 (Gabrb1), mRNA [NM_008069] |
KLA | .99 |
.98 |
.99 |
1.00 |
1.02 |
.99 |
.95 |
| ATP | 1.00 |
1.04 |
.98 |
1.01 |
1.05 |
1.02 |
1.03 |
| KLA/ATP | 1.00 |
.96 |
1.00 |
.96 |
1.05 |
1.03 |
1.04 |
|
| Gabrb2 |  |
NM_008070 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 2 (Gabrb2), mRNA [NM_008070] |
KLA | 1.04 |
1.04 |
1.03 |
1.04 |
1.00 |
.98 |
1.03 |
| ATP | .99 |
1.01 |
1.00 |
1.01 |
1.03 |
.99 |
.93 |
| KLA/ATP | 1.05 |
1.06 |
1.05 |
.96 |
.97 |
.94 |
1.00 |
|
| Gabrb3 |  |
NM_008071 |
gamma-aminobutyric acid (GABA-A) receptor, subunit beta 3 (Gabrb3), transcript variant 1, mRNA [NM_008071] |
KLA | .99 |
.99 |
.99 |
1.01 |
.99 |
.97 |
1.00 |
| ATP | .98 |
1.02 |
1.00 |
.99 |
.99 |
.99 |
1.00 |
| KLA/ATP | 1.00 |
1.03 |
1.05 |
.97 |
.98 |
.99 |
.99 |
|
| Gnai1 |  |
NM_010305 |
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] |
KLA | .95 |
1.01 |
1.01 |
1.00 |
1.09 |
1.10 |
1.08 |
| ATP | 1.06 |
1.06 |
.99 |
1.15 |
1.02 |
.94 |
.99 |
| KLA/ATP | 1.02 |
1.04 |
.99 |
1.16 |
1.01 |
1.02 |
1.13 |
|
| Gnai2 |  |
NM_008138 |
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] |
KLA | .74 |
.79 |
.82 |
.74 |
.91 |
.97 |
1.10 |
| ATP | 1.07 |
1.16 |
.78 |
1.12 |
.78 |
.48 |
.82 |
| KLA/ATP | .91 |
.81 |
.53 |
.80 |
.60 |
.68 |
.87 |
|
| Gnai3 |  |
NM_010306 |
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] |
KLA | 1.23 |
1.24 |
1.14 |
1.06 |
.99 |
1.15 |
1.09 |
| ATP | .96 |
.93 |
.86 |
.64 |
1.34 |
2.02 |
1.35 |
| KLA/ATP | 1.20 |
1.24 |
.97 |
.76 |
1.21 |
1.62 |
1.17 |
|
| Gnao1 |  |
NM_001113384 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] |
KLA | .95 |
.98 |
1.03 |
1.00 |
1.02 |
1.02 |
.99 |
| ATP | .95 |
1.02 |
1.01 |
1.08 |
.99 |
.97 |
.95 |
| KLA/ATP | 1.05 |
1.04 |
1.10 |
.99 |
1.01 |
.98 |
1.03 |
|
| Gnao1 | |
NM_010308 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] |
KLA | .98 |
.96 |
1.00 |
.97 |
.96 |
.97 |
1.01 |
| ATP | 1.12 |
.99 |
1.05 |
.87 |
.97 |
1.02 |
1.01 |
| KLA/ATP | .93 |
1.00 |
.99 |
1.01 |
1.05 |
1.07 |
.98 |
|
| Gnaq |  |
NM_008139 |
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] |
KLA | .82 |
.82 |
.69 |
.64 |
.60 |
.55 |
.55 |
| ATP | 1.06 |
1.02 |
.87 |
.67 |
.50 |
.66 |
.57 |
| KLA/ATP | .82 |
.79 |
.66 |
.55 |
.41 |
.33 |
.48 |
|
| Gnas |  |
AF107847 |
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] |
KLA | 1.04 |
.94 |
1.00 |
1.05 |
1.04 |
.98 |
1.00 |
| ATP | .98 |
.97 |
.96 |
1.00 |
.99 |
.98 |
1.02 |
| KLA/ATP | 1.04 |
1.02 |
.96 |
.95 |
1.01 |
.96 |
1.01 |
|
| Gnas | |
AK017423 |
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] |
KLA | .85 |
1.08 |
.97 |
.92 |
1.05 |
1.03 |
1.08 |
| ATP | .99 |
1.30 |
2.11 |
1.73 |
1.23 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.06 |
1.58 |
1.34 |
1.29 |
1.05 |
.91 |
|
| Gnas | |
NM_001077510 |
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] |
KLA | .99 |
1.03 |
.97 |
.91 |
1.03 |
.95 |
.97 |
| ATP | 1.04 |
1.19 |
1.15 |
1.61 |
1.24 |
.91 |
1.00 |
| KLA/ATP | 1.06 |
.97 |
1.01 |
1.46 |
1.04 |
.85 |
1.01 |
|
| Gnas | |
S49980 |
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] |
KLA | .91 |
.88 |
1.03 |
.87 |
.90 |
.84 |
1.01 |
| ATP | 1.16 |
1.22 |
1.02 |
1.55 |
1.16 |
.80 |
.99 |
| KLA/ATP | 1.01 |
1.13 |
.86 |
1.12 |
.97 |
.85 |
1.08 |
|
| Gnb1 |  |
NM_008142 |
guanine nucleotide binding protein (G protein), beta 1 (Gnb1), mRNA [NM_008142] |
KLA | 1.11 |
1.18 |
1.22 |
1.19 |
1.29 |
1.32 |
1.76 |
| ATP | 1.02 |
1.09 |
.84 |
.99 |
.97 |
.89 |
1.22 |
| KLA/ATP | 1.20 |
1.25 |
.85 |
1.01 |
.86 |
.91 |
1.57 |
|
| Gnb2 |  |
NM_010312 |
guanine nucleotide binding protein (G protein), beta 2 (Gnb2), mRNA [NM_010312] |
KLA | .94 |
.98 |
.94 |
1.08 |
1.23 |
1.32 |
1.16 |
| ATP | 1.04 |
.96 |
.59 |
.64 |
.59 |
.76 |
1.18 |
| KLA/ATP | 1.02 |
.84 |
.62 |
.64 |
.61 |
.89 |
1.36 |
|
| Gnb3 |  |
NM_013530 |
guanine nucleotide binding protein (G protein), beta 3 (Gnb3), mRNA [NM_013530] |
KLA | .99 |
1.00 |
.98 |
1.03 |
.94 |
.99 |
.96 |
| ATP | 1.01 |
1.02 |
.97 |
.95 |
1.01 |
.97 |
.92 |
| KLA/ATP | .99 |
1.02 |
1.02 |
.98 |
.99 |
.85 |
.99 |
|
| Gnb4 |  |
AK165084 |
2 days pregnant adult female ovary cDNA, RIKEN full-length enriched library, clone:E330002E21 product:guanine nucleotide binding protein, beta 4, full insert sequence [AK165084] |
KLA | 4.61 |
4.10 |
4.23 |
2.41 |
2.25 |
1.59 |
.93 |
| ATP | 1.21 |
1.17 |
1.04 |
.81 |
2.92 |
1.50 |
1.03 |
| KLA/ATP | 5.86 |
6.56 |
3.60 |
1.68 |
5.62 |
3.00 |
1.37 |
|
| Gnb4 | |
NM_013531 |
guanine nucleotide binding protein (G protein), beta 4 (Gnb4), mRNA [NM_013531] |
KLA | 8.41 |
8.09 |
10.57 |
9.44 |
6.06 |
2.97 |
.92 |
| ATP | 1.07 |
1.04 |
1.09 |
.87 |
1.48 |
2.10 |
1.18 |
| KLA/ATP | 8.14 |
8.93 |
9.12 |
7.69 |
5.03 |
5.11 |
2.37 |
|
| Gnb5 |  |
NM_010313 |
guanine nucleotide binding protein (G protein), beta 5 (Gnb5), transcript variant 1, mRNA [NM_010313] |
KLA | .68 |
.75 |
.67 |
.66 |
.53 |
.50 |
.65 |
| ATP | 1.03 |
1.08 |
1.09 |
1.14 |
.72 |
.54 |
.77 |
| KLA/ATP | .73 |
.70 |
.71 |
.73 |
.61 |
.65 |
.58 |
|
| Gng10 |  |
NM_025277 |
guanine nucleotide binding protein (G protein), gamma 10 (Gng10), mRNA [NM_025277] |
KLA | .95 |
.95 |
.86 |
.83 |
.70 |
.53 |
.43 |
| ATP | .93 |
1.03 |
1.17 |
1.21 |
.97 |
.60 |
.52 |
| KLA/ATP | .84 |
.91 |
.93 |
.99 |
.79 |
.47 |
.24 |
|
| Gng11 |  |
NM_025331 |
guanine nucleotide binding protein (G protein), gamma 11 (Gng11), mRNA [NM_025331] |
KLA | 1.30 |
1.26 |
1.44 |
1.54 |
1.26 |
1.42 |
1.90 |
| ATP | .88 |
.78 |
1.26 |
1.14 |
.90 |
.64 |
1.60 |
| KLA/ATP | 1.11 |
1.18 |
1.81 |
1.55 |
1.81 |
1.75 |
3.05 |
|
| Gng12 |  |
NM_025278 |
guanine nucleotide binding protein (G protein), gamma 12 (Gng12), mRNA [NM_025278] |
KLA | 2.21 |
2.23 |
2.48 |
2.62 |
2.47 |
2.28 |
1.68 |
| ATP | 1.02 |
1.02 |
1.09 |
1.10 |
1.20 |
1.32 |
1.01 |
| KLA/ATP | 2.10 |
2.17 |
2.38 |
2.40 |
1.91 |
1.60 |
1.77 |
|
| Gng13 |  |
NM_022422 |
guanine nucleotide binding protein (G protein), gamma 13 (Gng13), mRNA [NM_022422] |
KLA | 1.04 |
1.04 |
.94 |
1.00 |
1.00 |
1.05 |
.96 |
| ATP | 1.07 |
1.05 |
1.02 |
.94 |
.98 |
1.03 |
1.01 |
| KLA/ATP | 1.01 |
.99 |
1.05 |
1.01 |
1.01 |
.98 |
1.02 |
|
| Gng2 |  |
NM_010315 |
guanine nucleotide binding protein (G protein), gamma 2 (Gng2), transcript variant 1, mRNA [NM_010315] |
KLA | .79 |
.81 |
.81 |
.82 |
.67 |
.57 |
.75 |
| ATP | 1.02 |
1.01 |
1.13 |
1.35 |
1.48 |
1.01 |
1.31 |
| KLA/ATP | .79 |
.86 |
.97 |
1.05 |
1.29 |
1.00 |
.84 |
|
| Gng3 |  |
NM_010316 |
guanine nucleotide binding protein (G protein), gamma 3 (Gng3), mRNA [NM_010316] |
KLA | 1.00 |
.98 |
1.02 |
.95 |
.99 |
1.00 |
1.06 |
| ATP | .98 |
1.05 |
.99 |
1.03 |
1.05 |
1.03 |
.97 |
| KLA/ATP | 1.01 |
1.00 |
1.07 |
1.01 |
1.04 |
1.04 |
1.05 |
|
| Gng4 |  |
NM_010317 |
guanine nucleotide binding protein (G protein), gamma 4 (Gng4), mRNA [NM_010317] |
KLA | 1.27 |
1.26 |
1.47 |
1.30 |
1.15 |
1.13 |
.82 |
| ATP | 1.05 |
.97 |
1.07 |
1.62 |
3.97 |
3.46 |
1.24 |
| KLA/ATP | 1.35 |
1.32 |
1.37 |
1.35 |
1.64 |
2.18 |
1.56 |
|
| Gng5 |  |
NM_010318 |
guanine nucleotide binding protein (G protein), gamma 5 (Gng5), mRNA [NM_010318] |
KLA | .94 |
.84 |
.80 |
1.12 |
.98 |
1.11 |
1.29 |
| ATP | 1.07 |
1.01 |
1.07 |
1.05 |
1.17 |
1.52 |
1.01 |
| KLA/ATP | .83 |
.94 |
1.27 |
1.17 |
1.19 |
1.35 |
1.36 |
|
| Gng7 |  |
NM_001038655 |
guanine nucleotide binding protein (G protein), gamma 7 (Gng7), transcript variant 1, mRNA [NM_001038655] |
KLA | .92 |
.96 |
.87 |
.91 |
.83 |
.98 |
.98 |
| ATP | 1.04 |
1.06 |
.98 |
.95 |
.81 |
.77 |
.75 |
| KLA/ATP | .97 |
.95 |
.81 |
.91 |
.79 |
.77 |
.81 |
|
| Gng8 |  |
NM_010320 |
guanine nucleotide binding protein (G protein), gamma 8 (Gng8), mRNA [NM_010320] |
KLA | .93 |
.93 |
.95 |
.96 |
.90 |
.88 |
1.09 |
| ATP | .95 |
.90 |
1.01 |
.92 |
1.04 |
1.01 |
1.05 |
| KLA/ATP | .97 |
1.03 |
.99 |
.90 |
1.10 |
.99 |
1.04 |
|
| Gngt1 |  |
NM_010314 |
guanine nucleotide binding protein (G protein), gamma transducing activity polypeptide 1 (Gngt1), mRNA [NM_010314] |
KLA | 1.06 |
.99 |
.95 |
.98 |
1.03 |
1.10 |
.98 |
| ATP | .96 |
1.02 |
1.03 |
1.03 |
.94 |
1.06 |
.95 |
| KLA/ATP | .98 |
1.03 |
1.04 |
1.04 |
1.01 |
1.03 |
1.01 |
|
| Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
| Htr1a |  |
NM_008308 |
5-hydroxytryptamine (serotonin) receptor 1A (Htr1a), mRNA [NM_008308] |
KLA | .94 |
.96 |
1.04 |
1.00 |
.92 |
1.00 |
1.01 |
| ATP | 1.00 |
.93 |
1.03 |
1.03 |
1.03 |
.96 |
.99 |
| KLA/ATP | .98 |
.96 |
1.09 |
1.04 |
.97 |
1.08 |
1.03 |
|
| Htr1b |  |
NM_010482 |
5-hydroxytryptamine (serotonin) receptor 1B (Htr1b), mRNA [NM_010482] |
KLA | 1.12 |
.98 |
1.02 |
1.08 |
1.05 |
1.03 |
.97 |
| ATP | 1.01 |
1.00 |
.93 |
1.04 |
.95 |
1.27 |
1.02 |
| KLA/ATP | .98 |
.96 |
.97 |
1.04 |
1.04 |
1.00 |
1.10 |
|
| Htr1d |  |
NM_008309 |
5-hydroxytryptamine (serotonin) receptor 1D (Htr1d), mRNA [NM_008309] |
KLA | .99 |
1.01 |
1.00 |
1.02 |
1.00 |
1.00 |
.95 |
| ATP | .95 |
.93 |
.99 |
1.12 |
1.01 |
1.02 |
1.03 |
| KLA/ATP | .97 |
1.00 |
1.05 |
.97 |
.95 |
.96 |
.89 |
|
| Htr1f |  |
NM_008310 |
5-hydroxytryptamine (serotonin) receptor 1F (Htr1f), mRNA [NM_008310] |
KLA | 1.04 |
1.02 |
1.02 |
1.08 |
.98 |
1.03 |
1.05 |
| ATP | 1.03 |
1.08 |
1.06 |
.90 |
1.01 |
1.04 |
1.14 |
| KLA/ATP | 1.01 |
1.02 |
1.13 |
1.00 |
1.11 |
.98 |
1.03 |
|
| Htr2a |  |
NM_172812 |
5-hydroxytryptamine (serotonin) receptor 2A (Htr2a), mRNA [NM_172812] |
KLA | 1.00 |
1.01 |
1.03 |
1.00 |
.97 |
.96 |
.99 |
| ATP | .97 |
.97 |
.95 |
1.12 |
1.41 |
.98 |
.95 |
| KLA/ATP | .92 |
1.01 |
1.07 |
1.08 |
1.03 |
.98 |
1.06 |
|
| Htr2b |  |
NM_008311 |
5-hydroxytryptamine (serotonin) receptor 2B (Htr2b), mRNA [NM_008311] |
KLA | .47 |
.44 |
.41 |
.46 |
.73 |
1.91 |
1.14 |
| ATP | .90 |
.92 |
.95 |
1.02 |
1.24 |
1.47 |
11.87 |
| KLA/ATP | .44 |
.43 |
.51 |
.56 |
1.05 |
4.41 |
10.84 |
|
| Htr2c |  |
AK086348 |
15 days embryo head cDNA, RIKEN full-length enriched library, clone:D930023E13 product:5-hydroxytryptamine (serotonin) receptor 2C, full insert sequence. [AK086348] |
KLA | 1.01 |
1.01 |
1.00 |
1.03 |
1.03 |
1.04 |
1.04 |
| ATP | 1.01 |
1.00 |
1.00 |
1.04 |
1.02 |
1.03 |
.99 |
| KLA/ATP | .99 |
1.02 |
.96 |
1.07 |
1.03 |
1.06 |
1.06 |
|
| Htr2c | |
NM_008312 |
5-hydroxytryptamine (serotonin) receptor 2C (Htr2c), mRNA [NM_008312] |
KLA | 1.03 |
1.08 |
1.00 |
1.05 |
1.02 |
1.02 |
.98 |
| ATP | .96 |
1.02 |
1.01 |
1.05 |
.98 |
.99 |
1.03 |
| KLA/ATP | 1.00 |
1.00 |
1.04 |
.97 |
.96 |
.96 |
.98 |
|
| Htr3a |  |
M74425 |
gb|Mouse serotonin-gated ion channel (5HT3) mRNA, complete cds. [M74425] |
KLA | 1.11 |
.97 |
1.07 |
1.01 |
.97 |
1.03 |
1.04 |
| ATP | .95 |
.96 |
1.04 |
1.00 |
1.06 |
1.08 |
.97 |
| KLA/ATP | 1.02 |
1.02 |
.94 |
1.00 |
1.00 |
.97 |
.97 |
|
| Htr3b |  |
NM_020274 |
5-hydroxytryptamine (serotonin) receptor 3B (Htr3b), mRNA [NM_020274] |
KLA | 1.02 |
.95 |
.99 |
1.00 |
1.06 |
1.03 |
.94 |
| ATP | 1.05 |
1.01 |
.96 |
.95 |
1.04 |
1.02 |
1.00 |
| KLA/ATP | .94 |
1.06 |
1.01 |
.92 |
.99 |
.99 |
1.02 |
|
| Htr4 |  |
NM_008313 |
5 hydroxytryptamine (serotonin) receptor 4 (Htr4), mRNA [NM_008313] |
KLA | 1.02 |
1.05 |
.99 |
.99 |
1.01 |
.99 |
1.08 |
| ATP | .98 |
1.04 |
1.04 |
1.06 |
.96 |
1.02 |
1.06 |
| KLA/ATP | 1.00 |
.98 |
.97 |
1.03 |
1.02 |
1.08 |
1.00 |
|
| Htr5a |  |
NM_008314 |
5-hydroxytryptamine (serotonin) receptor 5A (Htr5a), mRNA [NM_008314] |
KLA | 1.08 |
1.01 |
1.14 |
1.10 |
1.13 |
1.04 |
1.08 |
| ATP | 1.09 |
.98 |
.96 |
.97 |
1.04 |
1.00 |
1.03 |
| KLA/ATP | 1.12 |
1.08 |
1.12 |
.99 |
1.00 |
1.03 |
.98 |
|
| Htr5b |  |
NM_010483 |
5-hydroxytryptamine (serotonin) receptor 5B (Htr5b), mRNA [NM_010483] |
KLA | .99 |
.98 |
1.01 |
.98 |
.97 |
.99 |
.98 |
| ATP | .95 |
1.00 |
1.01 |
1.01 |
1.01 |
1.06 |
.94 |
| KLA/ATP | .97 |
1.00 |
1.05 |
1.03 |
1.00 |
.93 |
1.06 |
|
| Htr6 |  |
NM_021358 |
5-hydroxytryptamine (serotonin) receptor 6 (Htr6), mRNA [NM_021358] |
KLA | 1.04 |
1.01 |
1.01 |
1.06 |
1.05 |
.98 |
.97 |
| ATP | 1.00 |
1.03 |
.96 |
.96 |
1.02 |
.96 |
1.02 |
| KLA/ATP | .93 |
.94 |
1.03 |
1.03 |
.91 |
1.00 |
.91 |
|
| Htr7 |  |
NM_008315 |
5-hydroxytryptamine (serotonin) receptor 7 (Htr7), mRNA [NM_008315] |
KLA | 1.07 |
.91 |
1.03 |
1.05 |
1.02 |
1.07 |
.97 |
| ATP | .97 |
1.02 |
1.00 |
1.03 |
1.05 |
1.05 |
.99 |
| KLA/ATP | 1.03 |
1.03 |
1.10 |
.99 |
.99 |
1.09 |
1.25 |
|
| Itpr1 |  |
NM_010585 |
inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] |
KLA | 3.66 |
3.69 |
6.74 |
8.11 |
7.08 |
4.40 |
1.22 |
| ATP | 1.08 |
.95 |
1.19 |
.94 |
1.09 |
1.00 |
.68 |
| KLA/ATP | 3.48 |
3.58 |
5.86 |
6.03 |
4.01 |
2.31 |
.97 |
|
| Itpr2 |  |
NM_019923 |
inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] |
KLA | 1.41 |
1.38 |
1.43 |
1.42 |
1.30 |
1.07 |
1.01 |
| ATP | 1.00 |
1.00 |
.97 |
.97 |
1.07 |
1.15 |
1.06 |
| KLA/ATP | 1.39 |
1.48 |
1.64 |
1.42 |
1.07 |
.83 |
.95 |
|
| Itpr3 |  |
NM_080553 |
inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] |
KLA | .55 |
.51 |
.45 |
.41 |
.34 |
.34 |
.45 |
| ATP | 1.01 |
.92 |
1.02 |
.57 |
.46 |
.34 |
1.22 |
| KLA/ATP | .56 |
.48 |
.48 |
.29 |
.33 |
.27 |
.65 |
|
| Kcnd2 |  |
NM_019697 |
potassium voltage-gated channel, Shal-related family, member 2 (Kcnd2), mRNA [NM_019697] |
KLA | .99 |
.98 |
1.02 |
.96 |
.99 |
1.00 |
1.05 |
| ATP | 1.02 |
1.01 |
.98 |
1.01 |
.98 |
.95 |
1.01 |
| KLA/ATP | 1.05 |
.98 |
1.05 |
.98 |
.99 |
1.01 |
1.06 |
|
| Kcnj3 |  |
BC068167 |
potassium inwardly-rectifying channel, subfamily J, member 3, mRNA (cDNA clone MGC:92970 IMAGE:30543982), complete cds [BC068167] |
KLA | .99 |
.97 |
1.01 |
.94 |
.97 |
.99 |
.99 |
| ATP | 1.06 |
1.01 |
1.03 |
.82 |
1.01 |
1.00 |
.94 |
| KLA/ATP | .98 |
.91 |
.99 |
.99 |
1.01 |
1.11 |
.97 |
|
| Kcnj3 | |
NM_008426 |
potassium inwardly-rectifying channel, subfamily J, member 3 (Kcnj3), mRNA [NM_008426] |
KLA | 1.05 |
.99 |
1.04 |
1.02 |
1.02 |
1.04 |
.94 |
| ATP | 1.00 |
1.01 |
1.02 |
.99 |
.96 |
1.03 |
1.04 |
| KLA/ATP | 1.00 |
.98 |
1.03 |
1.02 |
1.02 |
.96 |
1.06 |
|
| Kcnj5 |  |
NM_010605 |
potassium inwardly-rectifying channel, subfamily J, member 5 (Kcnj5), mRNA [NM_010605] |
KLA | 1.06 |
1.07 |
.97 |
.97 |
.99 |
1.05 |
.98 |
| ATP | .96 |
1.11 |
1.09 |
.98 |
.95 |
1.03 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.10 |
.98 |
1.07 |
.96 |
1.02 |
|
| Kcnj6 |  |
NM_001025585 |
potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2B, mRNA [NM_001025585] |
KLA | .97 |
.96 |
.95 |
.96 |
.98 |
.96 |
.95 |
| ATP | 1.00 |
.98 |
1.02 |
1.00 |
.98 |
.96 |
.97 |
| KLA/ATP | .98 |
.95 |
.99 |
.96 |
.98 |
.93 |
.96 |
|
| Kcnj6 | |
NM_010606 |
potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2A-1, mRNA [NM_010606] |
KLA | .96 |
1.03 |
.97 |
.98 |
.97 |
.99 |
1.07 |
| ATP | 1.08 |
.99 |
.99 |
1.05 |
.96 |
1.04 |
.97 |
| KLA/ATP | 1.01 |
.92 |
1.03 |
1.03 |
1.04 |
1.03 |
1.08 |
|
| Kcnj9 |  |
AK007011 |
adult male testis cDNA, RIKEN full-length enriched library, clone:1700085N21 product:unclassifiable, full insert sequence. [AK007011] |
KLA | 1.00 |
1.03 |
.98 |
1.02 |
.95 |
1.09 |
1.01 |
| ATP | .97 |
.92 |
1.03 |
1.11 |
1.02 |
.95 |
1.01 |
| KLA/ATP | 1.01 |
.98 |
.98 |
1.05 |
1.07 |
1.03 |
1.02 |
|
| Kcnj9 | |
NM_008429 |
potassium inwardly-rectifying channel, subfamily J, member 9 (Kcnj9), mRNA [NM_008429] |
KLA | 1.03 |
1.06 |
1.06 |
1.07 |
1.09 |
.95 |
1.00 |
| ATP | 1.02 |
.93 |
.93 |
1.14 |
1.07 |
.98 |
.95 |
| KLA/ATP | 1.03 |
.99 |
.99 |
1.02 |
1.02 |
.96 |
.96 |
|
| Kcnn2 |  |
NM_080465 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 (Kcnn2), mRNA [NM_080465] |
KLA | 1.00 |
1.02 |
1.00 |
1.03 |
1.02 |
1.01 |
1.01 |
| ATP | 1.00 |
1.00 |
1.02 |
1.01 |
1.01 |
1.01 |
1.02 |
| KLA/ATP | .99 |
1.02 |
1.01 |
1.01 |
1.02 |
.99 |
1.00 |
|
| Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
| Maoa |  |
NM_173740 |
monoamine oxidase A (Maoa), nuclear gene encoding mitochondrial protein, mRNA [NM_173740] |
KLA | 1.14 |
1.11 |
1.06 |
1.07 |
.84 |
.55 |
.53 |
| ATP | 1.10 |
1.07 |
1.33 |
1.20 |
1.44 |
2.37 |
1.38 |
| KLA/ATP | .97 |
1.11 |
1.75 |
1.33 |
1.27 |
1.21 |
1.09 |
|
| Maob |  |
NM_172778 |
monoamine oxidase B (Maob), nuclear gene encoding mitochondrial protein, mRNA [NM_172778] |
KLA | 1.01 |
.97 |
1.01 |
1.05 |
1.01 |
.95 |
1.01 |
| ATP | 1.09 |
.98 |
.99 |
.97 |
1.03 |
1.03 |
.94 |
| KLA/ATP | 1.02 |
1.05 |
.99 |
1.02 |
1.00 |
.98 |
.98 |
|
| Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
| Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
| Mapk1 | |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
| Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mm.22094
6 |  |
27545180 |
Unknown |
KLA | 1.00 |
.93 |
.97 |
1.05 |
1.06 |
1.29 |
1.13 |
| ATP | .90 |
.94 |
1.25 |
1.18 |
.85 |
.62 |
1.20 |
| KLA/ATP | .86 |
.99 |
1.14 |
.99 |
.83 |
.70 |
1.26 |
|
Mm.23904
1 |  |
145301574 |
Unknown |
KLA | 4.48 |
4.00 |
7.76 |
10.91 |
8.92 |
5.66 |
4.86 |
| ATP | 4.23 |
6.26 |
25.25 |
43.30 |
8.11 |
8.22 |
2.78 |
| KLA/ATP | 6.59 |
8.15 |
19.54 |
43.73 |
11.92 |
15.37 |
15.81 |
|
Mm.26915
|  |
51921286 |
Unknown |
KLA | 1.02 |
1.03 |
.96 |
1.11 |
1.05 |
.96 |
.96 |
| ATP | 1.02 |
1.00 |
.98 |
1.06 |
1.04 |
.99 |
1.08 |
| KLA/ATP | .96 |
.94 |
1.06 |
1.00 |
1.02 |
1.00 |
1.03 |
|
Mm.28967
2 |  |
133893229 |
Unknown |
KLA | 1.01 |
1.03 |
1.00 |
.97 |
.97 |
1.02 |
1.02 |
| ATP | .97 |
.98 |
.92 |
1.05 |
.98 |
.99 |
1.07 |
| KLA/ATP | .93 |
1.03 |
.95 |
.99 |
1.02 |
1.04 |
1.05 |
|
Mm.33050
7 |  |
67906182 |
Unknown |
KLA | .94 |
.98 |
.99 |
1.03 |
1.05 |
1.07 |
.98 |
| ATP | .95 |
1.02 |
.97 |
.98 |
.99 |
1.05 |
1.02 |
| KLA/ATP | 1.02 |
1.05 |
1.01 |
1.03 |
.99 |
.98 |
.97 |
|
Mm.41137
|  |
148747308 |
Unknown |
KLA | 1.03 |
1.00 |
.95 |
.92 |
1.04 |
.98 |
.96 |
| ATP | 1.02 |
.98 |
.98 |
.90 |
.95 |
.92 |
1.07 |
| KLA/ATP | .91 |
.89 |
1.01 |
.95 |
1.00 |
.96 |
.99 |
|
Mm.42607
7 |  |
58743309 |
Unknown |
KLA | .98 |
.93 |
1.04 |
1.03 |
.97 |
.98 |
1.16 |
| ATP | 1.02 |
.95 |
1.02 |
1.06 |
.96 |
.95 |
1.04 |
| KLA/ATP | .98 |
.97 |
.98 |
1.01 |
.99 |
1.11 |
.91 |
|
Mm.44050
5 |  |
84579905 |
Unknown |
KLA | 1.03 |
.96 |
.90 |
1.03 |
.94 |
1.15 |
1.23 |
| ATP | .88 |
.91 |
1.15 |
1.18 |
1.17 |
1.31 |
1.02 |
| KLA/ATP | .87 |
.97 |
1.19 |
1.18 |
1.36 |
1.34 |
1.25 |
|
Mm.44160
1 |  |
145966786 |
Unknown |
KLA | 1.08 |
.94 |
1.01 |
.97 |
.79 |
.78 |
.71 |
| ATP | 1.09 |
.92 |
1.10 |
.75 |
.65 |
.92 |
.69 |
| KLA/ATP | 1.01 |
.92 |
1.16 |
.81 |
.69 |
.56 |
.63 |
|
| Mm.4424 |  |
110225367 |
Unknown |
KLA | .99 |
.93 |
1.01 |
1.02 |
1.00 |
.92 |
1.00 |
| ATP | .98 |
1.03 |
3.11 |
1.13 |
1.19 |
1.03 |
1.11 |
| KLA/ATP | .95 |
.97 |
.97 |
.96 |
.93 |
1.01 |
.99 |
|
| Mm.4716 |  |
162135953 |
Unknown |
KLA | 1.04 |
1.03 |
.98 |
.99 |
.98 |
.99 |
1.08 |
| ATP | 1.01 |
1.06 |
1.08 |
1.07 |
1.09 |
1.03 |
1.05 |
| KLA/ATP | .99 |
.93 |
1.03 |
1.14 |
1.03 |
1.09 |
1.00 |
|
| Mm.4831 |  |
153791844 |
Unknown |
KLA | 1.05 |
1.00 |
.98 |
1.01 |
1.02 |
.98 |
.91 |
| ATP | .99 |
1.05 |
1.08 |
.90 |
.95 |
1.07 |
1.01 |
| KLA/ATP | .97 |
1.01 |
1.04 |
.96 |
.96 |
.97 |
1.05 |
|
| Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
| Pla2g4a |  |
NM_008869 |
phospholipase A2, group IVA (cytosolic, calcium-dependent) (Pla2g4a), mRNA [NM_008869] |
KLA | 3.93 |
4.49 |
4.86 |
6.40 |
6.44 |
3.10 |
1.68 |
| ATP | 1.13 |
1.36 |
1.27 |
1.30 |
1.02 |
5.37 |
1.47 |
| KLA/ATP | 3.64 |
4.45 |
4.76 |
7.11 |
2.96 |
4.08 |
2.60 |
|
| Pla2g4b |  |
NM_145378 |
phospholipase A2, group IVB (cytosolic) (Pla2g4b), mRNA [NM_145378] |
KLA | 1.09 |
1.18 |
.95 |
1.01 |
.97 |
.97 |
.77 |
| ATP | 1.05 |
1.14 |
1.28 |
.94 |
.88 |
1.18 |
.70 |
| KLA/ATP | 1.23 |
1.43 |
1.21 |
1.02 |
1.15 |
1.16 |
.78 |
|
| Pla2g4c |  |
AK145339 |
1 cell embryo 1 cell cDNA, RIKEN full-length enriched library, clone:I0C0013F18 product:weakly similar to Cytosolic phospholipase A2 gamma [Homo sapiens], full insert sequence [AK145339] |
KLA | 1.09 |
1.21 |
1.33 |
1.17 |
1.26 |
1.30 |
1.05 |
| ATP | .97 |
1.06 |
1.00 |
.98 |
.98 |
.98 |
1.05 |
| KLA/ATP | 1.19 |
1.16 |
1.18 |
1.13 |
1.04 |
1.02 |
1.06 |
|
| Pla2g4c | |
NM_001004762 |
phospholipase A2, group IVC (cytosolic, calcium-independent) (Pla2g4c), mRNA [NM_001004762] |
KLA | .93 |
1.00 |
.94 |
.93 |
.94 |
.94 |
.96 |
| ATP | .98 |
.96 |
1.13 |
.97 |
.99 |
.89 |
.96 |
| KLA/ATP | 1.01 |
1.01 |
1.07 |
1.01 |
.94 |
1.01 |
.92 |
|
| Pla2g4e |  |
AK049063 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230096D22 product:hypothetical Lysophospholipase catalytic domain containing protein, full insert sequence. [AK049063] |
KLA | 1.03 |
1.09 |
1.01 |
1.01 |
1.06 |
.94 |
1.05 |
| ATP | 1.03 |
1.00 |
1.06 |
1.01 |
.96 |
1.05 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.01 |
.98 |
1.03 |
.95 |
1.01 |
|
| Pla2g4e | |
NM_177845 |
phospholipase A2, group IVE (Pla2g4e), mRNA [NM_177845] |
KLA | .97 |
.95 |
1.01 |
.97 |
1.02 |
1.03 |
1.05 |
| ATP | .98 |
.99 |
1.00 |
1.10 |
.98 |
1.00 |
1.02 |
| KLA/ATP | 1.05 |
.93 |
.96 |
1.03 |
1.08 |
1.05 |
.99 |
|
| Pla2g4f |  |
NM_001024145 |
phospholipase A2, group IVF (Pla2g4f), mRNA [NM_001024145] |
KLA | 1.08 |
.99 |
1.04 |
1.02 |
1.04 |
.98 |
1.01 |
| ATP | .99 |
1.04 |
.99 |
1.03 |
1.12 |
1.01 |
1.25 |
| KLA/ATP | .97 |
1.04 |
1.10 |
1.06 |
1.04 |
1.03 |
1.03 |
|
| Plcb1 |  |
AK129166 |
mRNA for mKIAA0581 protein [AK129166] |
KLA | 1.02 |
.98 |
.91 |
.91 |
.92 |
.95 |
.89 |
| ATP | 1.03 |
1.02 |
1.02 |
1.01 |
.90 |
1.02 |
1.04 |
| KLA/ATP | .98 |
.97 |
.91 |
.93 |
.92 |
1.01 |
1.16 |
|
| Plcb1 | |
NM_019677 |
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] |
KLA | .99 |
.94 |
.95 |
.97 |
.93 |
.92 |
.91 |
| ATP | 1.00 |
.96 |
.99 |
.95 |
.99 |
1.03 |
.98 |
| KLA/ATP | .93 |
.96 |
.94 |
.93 |
.87 |
1.00 |
1.06 |
|
| Plcb2 |  |
NM_177568 |
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] |
KLA | .70 |
.68 |
.64 |
.67 |
.65 |
.76 |
.88 |
| ATP | .95 |
.94 |
1.04 |
.94 |
.72 |
.57 |
1.19 |
| KLA/ATP | .69 |
.68 |
.72 |
.63 |
.65 |
.55 |
.70 |
|
| Plcb3 |  |
NM_008874 |
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] |
KLA | 1.72 |
1.78 |
1.82 |
1.65 |
1.67 |
1.44 |
1.21 |
| ATP | .97 |
1.04 |
.81 |
.87 |
.78 |
.88 |
.94 |
| KLA/ATP | 1.69 |
1.89 |
1.44 |
1.66 |
1.12 |
.73 |
.93 |
|
| Plcb4 |  |
AK082509 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] |
KLA | 1.06 |
1.03 |
.97 |
.98 |
1.02 |
1.01 |
.99 |
| ATP | .99 |
1.07 |
1.09 |
.95 |
.97 |
.97 |
1.02 |
| KLA/ATP | .98 |
1.00 |
1.03 |
.96 |
1.02 |
.91 |
.98 |
|
| Plcb4 | |
NM_013829 |
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] |
KLA | .88 |
.94 |
.81 |
.82 |
.81 |
.86 |
1.01 |
| ATP | 1.00 |
1.01 |
.92 |
.93 |
.88 |
.85 |
.89 |
| KLA/ATP | .97 |
.94 |
.78 |
.80 |
.78 |
.86 |
.97 |
|
| Prkaca |  |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
| Prkacb |  |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
| Prkca |  |
NM_011101 |
protein kinase C, alpha (Prkca), mRNA [NM_011101] |
KLA | 1.00 |
.96 |
.94 |
.95 |
.95 |
.89 |
.96 |
| ATP | 1.00 |
1.03 |
.91 |
.94 |
.82 |
.87 |
1.13 |
| KLA/ATP | 1.02 |
.95 |
.91 |
.86 |
.78 |
.84 |
.94 |
|
| Prkcb1 |  |
NM_008855 |
protein kinase C, beta 1 (Prkcb1), mRNA [NM_008855] |
KLA | .92 |
.95 |
.93 |
.78 |
.77 |
1.08 |
1.83 |
| ATP | 1.03 |
1.12 |
1.09 |
1.23 |
.90 |
2.08 |
.96 |
| KLA/ATP | .98 |
.99 |
.82 |
.89 |
.62 |
1.01 |
1.08 |
|
| Prkcc |  |
NM_011102 |
protein kinase C, gamma (Prkcc), mRNA [NM_011102] |
KLA | 1.02 |
1.04 |
1.11 |
1.04 |
.96 |
1.02 |
1.05 |
| ATP | .98 |
.98 |
1.05 |
1.03 |
1.08 |
.96 |
.95 |
| KLA/ATP | 1.21 |
1.16 |
1.09 |
1.07 |
1.04 |
.98 |
.93 |
|
| Prkx |  |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
| Ptgs1 |  |
NM_008969 |
prostaglandin-endoperoxide synthase 1 (Ptgs1), mRNA [NM_008969] |
KLA | .74 |
.74 |
.76 |
.74 |
.61 |
.53 |
.18 |
| ATP | 1.01 |
1.05 |
1.29 |
1.14 |
.99 |
1.16 |
3.96 |
| KLA/ATP | .77 |
.71 |
.88 |
.77 |
.75 |
.61 |
.40 |
|
| Ptgs2 |  |
NM_011198 |
prostaglandin-endoperoxide synthase 2 (Ptgs2), mRNA [NM_011198] |
KLA | 181.04 |
220.88 |
218.58 |
132.79 |
103.05 |
22.69 |
18.02 |
| ATP | 2.47 |
9.45 |
52.13 |
208.62 |
271.22 |
306.11 |
6.86 |
| KLA/ATP | 233.39 |
387.29 |
617.86 |
###.## |
608.44 |
290.80 |
112.22 |
|
| Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
| Raf1 | |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
| Rapgef3 |  |
NM_144850 |
Rap guanine nucleotide exchange factor (GEF) 3 (Rapgef3), mRNA [NM_144850] |
KLA | .25 |
.26 |
.26 |
.25 |
.35 |
.62 |
.92 |
| ATP | .91 |
.81 |
.96 |
.98 |
3.37 |
.70 |
1.85 |
| KLA/ATP | .22 |
.25 |
.36 |
.39 |
3.25 |
1.14 |
.67 |
|
| Slc18a1 |  |
AK049514 |
7 days embryo whole body cDNA, RIKEN full-length enriched library, clone:C430018J19 product:CHROMAFFIN GRANULE AMINE TRANSPORTER (VESICULAR AMINE TRANSPORTER 1) (VAT1) homolog [Rattus norvegicus], full insert sequence. [AK049514] |
KLA | 1.08 |
1.09 |
1.04 |
1.02 |
1.06 |
1.01 |
.99 |
| ATP | .98 |
.94 |
.98 |
.98 |
1.08 |
.98 |
1.03 |
| KLA/ATP | 1.01 |
.97 |
.94 |
1.06 |
1.03 |
1.01 |
1.24 |
|
| Slc18a1 | |
NM_153054 |
solute carrier family 18 (vesicular monoamine), member 1 (Slc18a1), mRNA [NM_153054] |
KLA | 1.13 |
1.10 |
1.33 |
1.27 |
1.37 |
1.41 |
1.56 |
| ATP | .86 |
.78 |
.83 |
.61 |
.70 |
.45 |
1.22 |
| KLA/ATP | .96 |
1.02 |
.92 |
.73 |
.94 |
.90 |
4.36 |
|
| Slc18a2 |  |
NM_172523 |
solute carrier family 18 (vesicular monoamine), member 2 (Slc18a2), mRNA [NM_172523] |
KLA | .98 |
.97 |
.95 |
.94 |
.94 |
.99 |
.92 |
| ATP | .98 |
1.01 |
.96 |
.95 |
.96 |
.96 |
.98 |
| KLA/ATP | .91 |
.94 |
.91 |
.92 |
.96 |
.95 |
.93 |
|
| Slc6a4 |  |
NM_010484 |
solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 (Slc6a4), mRNA [NM_010484] |
KLA | 2.29 |
2.79 |
3.19 |
3.16 |
3.52 |
3.33 |
1.20 |
| ATP | .96 |
1.12 |
1.10 |
1.08 |
1.03 |
1.17 |
1.29 |
| KLA/ATP | 2.27 |
2.48 |
2.20 |
2.26 |
1.77 |
1.73 |
2.56 |
|
| Tph1 |  |
NM_009414 |
tryptophan hydroxylase 1 (Tph1), mRNA [NM_009414] |
KLA | .99 |
1.02 |
1.03 |
1.03 |
1.01 |
1.00 |
1.03 |
| ATP | 1.07 |
1.04 |
1.01 |
1.02 |
.99 |
.98 |
.98 |
| KLA/ATP | 1.00 |
1.07 |
1.05 |
1.37 |
1.20 |
1.03 |
.99 |
|
| Tph2 |  |
AY090565 |
neuronal tryptophan hydroxylase (Ntph) mRNA, complete cds [AY090565] |
KLA | 1.01 |
.98 |
.98 |
1.05 |
.96 |
.97 |
1.05 |
| ATP | .94 |
1.04 |
.95 |
.93 |
.97 |
.91 |
.95 |
| KLA/ATP | 1.06 |
1.07 |
.99 |
.99 |
1.05 |
1.06 |
.98 |
|
| Trpc1 |  |
AK038676 |
adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230054C16 product:transient receptor potential cation channel, subfamily C, member 1, full insert sequence. [AK038676] |
KLA | .99 |
.96 |
1.07 |
1.00 |
1.03 |
.97 |
.95 |
| ATP | .99 |
1.01 |
1.03 |
1.01 |
1.01 |
1.04 |
.94 |
| KLA/ATP | .94 |
1.02 |
.95 |
.96 |
.97 |
.95 |
1.00 |
|
| Trpc1 | |
NM_011643 |
transient receptor potential cation channel, subfamily C, member 1 (Trpc1), mRNA [NM_011643] |
KLA | 1.06 |
1.05 |
.97 |
1.08 |
1.06 |
1.00 |
1.06 |
| ATP | 1.04 |
.93 |
.99 |
.97 |
.91 |
1.00 |
.94 |
| KLA/ATP | 1.04 |
1.04 |
.86 |
1.01 |
.97 |
.95 |
.96 |
|
: View data/graphs for replicates
ATP
ATP+KLA